摘要:
A novel megakaryocyte differentiation factor, for example, consisting essentially of SEQ ID NO: 30; DNA coding for the megakaryocyte differentiation factor, an expression vector comprising the DNA, a host transformed with the expression vector, and a process for production of the megakaryocyte differentiation factor using the host.The megakaryocyte differentiation factor accelerates differentiation of megakaryocytes in the presence of IL-3, and acts as a thrombopoietin, and therefore an effective medicament to various diseases involving a decrease in platelete.
摘要:
The present invention provides novel megakaryocyte differentiation factors, which are useful as therapeutic agents due to their accelerating effects on the differentiation of megakaryocytes and their thrombopoietic effects. The megakaryocyte differentiation factors of the present invention include the megakaryocyte differentiation factor having the amino acid sequence shown in SEQ ID NO: 34. The present invention also provides DNA coding for the megakaryocyte differentiation factors of the present invention, expression vectors containing the DNA, hosts transformed with the expression vectors, and processes for production of the megakaryocyte differentiation factors using transformed hosts. The present invention further provides specific antibodies to the megakaryocyte differentiation factors of the present invention.
摘要翻译:本发明提供了新的巨核细胞分化因子,由于它们对巨核细胞的分化及其血小板生成作用的加速作用,它们可用作治疗剂。 本发明的巨核细胞分化因子包括具有SEQ ID NO:34所示的氨基酸序列的巨核细胞分化因子。本发明还提供编码本发明的巨核细胞分化因子的DNA,含有该DNA的表达载体,宿主 用表达载体转化,以及使用转化宿主生产巨核细胞分化因子的过程。 本发明还提供了针对本发明的巨核细胞分化因子的特异性抗体。
摘要:
A novel megakaryocyte differentiation factor, for example, consisting essentially of SEQ ID NO: 30; DNA coding for the megakaryocyte differentiation factor, an expression vector comprising the DNA, a host transformed with the expression vector, and a process for production of the megakaryocyte differentiation factor using the host. The megakaryocyte differentiation factor accelerates differentiation of megakaryocytes in the presence of IL-3, and acts as a thrombopoietin, and therefore an effective medicament to various diseases involving a decrease in platelete.
摘要翻译:一种新型巨核细胞分化因子,例如基本上由SEQ ID NO:30组成; 编码巨核细胞分化因子的DNA,包含DNA的表达载体,用表达载体转化的宿主以及使用该宿主产生巨核细胞分化因子的方法。 巨核细胞分化因子加速了在IL-3存在下巨核细胞的分化,并且作为血小板生成素,因此是涉及减少血小板的各种疾病的有效药物。
摘要:
There are provided a human BSSP6 serine protease and a pharmaceutical composition containing this serine protease. Also provided is an antibody to this serine protease or to a fragment thereof.
摘要:
A monoclonal antibody binding selectively to neurosin obtained from hybridomas, in particular, strain 2B2-6 and strain S2E5 showing stable proliferation ability. These hydridomas are obtained by fusing mouse spleen cells having a high antibody titer against neurosin with mouse-derived myeloma cells, screening fused cells being highly reactive with neurosin, and thus producing an antibody binding specifically to neurosin. By using this antibody, various diseases in which neurosin participates can be diagnosed.
摘要:
A .beta.1,6-N-acetylglucosaminyl transferase having the following properties: (1) Action: it transfers N-acetylglucosamine from UDP-N-acetylglucosamine to .alpha.-6-D-mannoside; (2) Substrate specificity: it shows a reactivity of about 79% for GnGnF-bi-PA, about 125% for GnGnGn-tri-PA and about 66% for GnM-Pa, when taking a reactivity for GnGn-bi-PA as 100%; (3) Optimum pH: 6.2 to 6.3; (4) Inhibition, Activation and Stability: Mn.sup.2+ is not necessary for expression of activity, and the activity is not inhibited in the presence of 20 mM EDTA; (5) Molecular weight: about 73,000 as determined by SDS-PAGE in the absence of reducing agent; and about 73,000 and about 60,000 as determined in the presence of a reducing agent; (6) Km value: 133 .mu.M and 3.5 mM for acceptor GnGn-bi-PA and donor UDP-GlcNAc, respectively; and (7) It includes the following peptide fragments: (SEQ ID NO.1) Thr-Pro-Trp-Gly-Lys (SEQ ID NO.2) Asn-Ile-Pro-Ser-Tyr-Val (SEQ ID NO.3) Val-Leu-Asp-Ser-Phe-Gly-Thr-Glu-Pro-Glu-Phe-Asn-His-Ala-Asn-Tyr-Ala (SEQ ID NO.4) Asp-Leu-Gln-Phe-Leu-Leu (SEQ ID NO.5) Asn-Thr-Asp-Phe-Phe-Ile-Gly, and gene coding for said enzyme, and a process for production of the enzyme.
摘要翻译:具有以下性质的β1,6-己酰氨基葡糖转移酶:(1)作用:将N-乙酰葡糖胺从UDP-N-乙酰葡糖胺转移至α-6-D-甘露糖苷; (2)底物特异性:对GnGnF-bi-PA显示出约79%的反应性,GnGnGn-tri-PA为约125%,GnM-Pa为约66% 100%; (3)最适pH:6.2〜6.3; (4)抑制,活化和稳定性:Mn2 +对于表达活性不是必需的,并且在20mM EDTA存在下不能抑制活性; (5)分子量:不含还原剂时通过SDS-PAGE测定的约73,000; 约73,000和约60,000,在还原剂存在下测定; (6)Km值分别为133μM和3.5mM,分别为受体GnGn-bi-PA和供体UDP-GlcNAc; (7)它包括以下肽片段:(SEQ ID NO.1)Thr-Pro-Trp-Gly-Lys(SEQ ID NO.2)Asn-Ile-Pro-Ser-Tyr-Val(SEQ ID NO: 3)Val-Leu-Asp-Ser-Phe-Gly-Thr-Glu-Pro-Glu-Phe-Asn-His-Ala-Asn-Tyr-Ala(SEQ ID NO.4)Asp-Leu-Gln-Phe- Leu-Leu(SEQ ID NO.5)Asn-Thr-Asp-Phe-Phe-Ile-Gly,以及编码所述酶的基因及其制备方法。
摘要:
A novel megakaryocyte potentiator (Meg-POT) of human origin is provided. This Meg-POT has a molecular weight of about 32,000 in SDS-PAGE. In addition, this megakaryocyte potentiator contains the following amino acid sequence in its molecule:Gly Glu Thr Gly Gln Glu Ala Ala Pro Leu Asp Gly Val Leu. (SEQ. I.D. No. 1)This Meg-POT is useful as a therapeutic preparation for disorders caused by decreased platelets or platelet hypofunction.
摘要翻译:PCT No.PCT / JP92 / 01689 Sec。 371日期1994年6月27日第 102(e)日期1994年6月27日PCT提交1992年12月24日PCT公布。 公开号WO93 / 13132 日期:1994年7月8日。提供了一种人源的新型巨核细胞增强子(Meg-POT)。 该Meg-POT在SDS-PAGE中的分子量约为32,000。 此外,该巨核细胞增强剂在其分子中含有以下氨基酸序列:Gly Glu Thr Gly Gln Glu Ala Ala Pro Leu Asp Gly Val Leu。 (SEQ.ID.D. No.1)该Meg-POT可用作由血小板减少或血小板功能减退引起的疾病的治疗剂。
摘要:
There are provided proteins having the amino acid sequences represented by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20; proteins having amino acid sequences derived from these amino acid sequences by deletion, substitution or addition of one to several amino acids; and nucleotide sequences encoding the same; transgenic non-human animals with altered expression level of a serine protease BSSP4; an antibody against BSSP4; and a method for detecting BSSP4 in a specimen by using the antibody.
摘要翻译:提供具有由SEQ ID NO:2,4,6,8,10,12,14,16,18和20表示的氨基酸序列的蛋白质; 具有通过缺失,取代或添加一至数个氨基酸从这些氨基酸序列衍生的氨基酸序列的蛋白质; 和编码其的核苷酸序列; 具有改变的表达水平的丝氨酸蛋白酶BSSP4的转基因非人动物; 针对BSSP4的抗体; 以及通过使用抗体检测标本中的BSSP4的方法。
摘要:
There are provided a human BSSP6 serine protease and a pharmaceutical composition containing this serine protease. Also provided is an antibody to this serine protease or to a fragment thereof.
摘要:
There are provided proteins having the amino acid sequences represented by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20; proteins having amino acid sequences derived from these amino acid sequences by deletion, substitution or addition of one to several amino acids; and nucleotide sequences encoding the same; transgenic non-human animals with altered expression level of a serine protease BSSP4; an antibody against BSSP4; and a method for detecting BSSP4 in a specimen by using the antibody.
摘要翻译:提供具有由SEQ ID NO:2,4,6,8,10,12,14,16,18和20表示的氨基酸序列的蛋白质; 具有通过缺失,取代或添加一至数个氨基酸从这些氨基酸序列衍生的氨基酸序列的蛋白质; 和编码其的核苷酸序列; 具有改变的表达水平的丝氨酸蛋白酶BSSP4的转基因非人动物; 针对BSSP4的抗体; 以及通过使用抗体检测标本中的BSSP4的方法。